Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

OptiNose raises $37mm in Series D round

Executive Summary

OptiNose Inc. (ENT/allergy therapeutics) raised $37mm in a Series D round led by new backer Fidelity Management & Research Co. Returning investors Avista Capital Partners, Entrepreneurs Fund, and others also participated. Earlier this year the company filed an NDA for OPN375 (fluticasone propionate), a glucocorticoid receptor for nasal polyposis; FDA approval is expected in Q3 2017. OptiNose will use proceeds from this offering to support OPN375's anticipated 2018 commercial launch. The company has raised $129.1mm to date.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies